BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30

• Business

  Iterum Therapeutics Reports Third Quarter 2022 Financial Results

  Iterum Therapeutics plc, a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, reported financial results for the third quarter ended September 30, 2022.

  November 10, 2022

   · 

  14 min read
• Business

  Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

  Passage Bio, Inc. provided business updates and reported financial results for the third quarter ended September 30, 2022.

  November 10, 2022

   · 

  10 min read
• Business

  Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights

  Tango Therapeutics, Inc., a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the third quarter ended September 30, 2022, and provided business highlights.

  November 10, 2022

   · 

  14 min read
• Business

  IsoPlexis Reports Third Quarter 2022 Financial Results

  IsoPlexis Corporation, a company empowering labs to leverage the cells and proteome changing the course of human health, reported financial results for the quarter ended September 30, 2022.

  November 10, 2022

   · 

  9 min read
• Business

  Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

  Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2022.

  November 10, 2022

   · 

  9 min read
• Business

  Finch Therapeutics Provides Corporate Updates and Reports Third Quarter 2022 Financial Results

  Finch Therapeutics Group, Inc. provided corporate updates and reported financial results for the third quarter ended September 30, 2022.

  November 10, 2022

   · 

  12 min read
• Business

  Humacyte Third Quarter 2022 Financial Results and Business Update

  Humacyte, Inc. announced financial results for the third quarter ended September 30, 2022, and highlighted recent corporate accomplishments.

  November 10, 2022

   · 

  16 min read
• Business

  Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

  Larimar Therapeutics, Inc., a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, reported its third quarter 2022 operating and financial results.

  November 10, 2022

   · 

  10 min read
• Pharm Country

  Tiziana Life Sciences Announces Near-Term Strategic Focus on Intranasal Foralumab for Diseases of the Central Nervous System (CNS)

  Tiziana Life Sciences Ltd. announced a corporate update, including its near-term focus on developing intranasal foralumab for inflammatory diseases of the Central Nervous System such as non-active secondary-progressive Multiple Sclerosis, Alzheimer’s disease and amyotrophic lateral sclerosis.

  November 10, 2022

   · 

  4 min read
• Business

  atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

  atai Life Sciences N.V. reported financial results for the quarter ended September 30, 2022 and provided a business update.

  November 10, 2022

   · 

  14 min read